3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Conditions
Carcinoma, Non-Small-Cell Lung
3
Breast Neoplasms
3
Brain Neoplasms
3
Uterine Cervical Neoplasms
2
Lung Neoplasms
2
Leukemia, Myeloid, Acute
2
Vulvar Neoplasms
1
Vaginal Neoplasms
1
Uterine Neoplasms
1
Stomach Neoplasms
1
Rectal Neoplasms
1
Prostatic Neoplasms
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Neoplasms
1
Neoplasm Metastasis
1
Myelodysplastic Syndromes
1
Melanoma
1
Lymphatic Metastasis
1
Leukemia, Myelomonocytic, Chronic
1
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
1
Head and Neck Neoplasms
1
Endometrial Neoplasms
1
Breast Neoplasms, Male
1
Anus Neoplasms
1
Interventions
Platinum
2
Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18
2
Cisplatin
2
Biopsy
2
1,2-diaminocyclohexaneplatinum II citrate
2
rocakinogene sifuplasmid
1
fludarabine phosphate
1
fludarabine
1
durvalumab
1
alovudine
1
aldesleukin
1
Vaccines, Synthetic
1
VGX-3100
1
Sonazoid
1
Respiratory Function Tests
1
Radiotherapy, Intensity-Modulated
1
Radiotherapy, Conformal
1
Radiosurgery
1
Prochlorperazine
1
Positron-Emission Tomography
1
Ondansetron
1
O(6)-codeine methyl ether
1
Meperidine
1
Magnetic Resonance Imaging
1
MEDI0457
1
Loperamide
1
Interleukin-2
1
Innovar
1
Indomethacin
1
Immunoglobulin G
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has results
×
Vulvar Neoplasms
×
alovudine
×
Clear all
NCT01399658
2023-03-14
AMIGO
Dana-Farber Cancer Institute
Phase 2
Completed
93 enrolled
5 charts